BIOTECHNOLOGY
Peptide Quality Infrastructure for Biotechnology
Quality risk assessment, early analytical development and impurity strategy for new peptide programs — from discovery through IND-enabling studies.
FOCUS AREAS
Quality Infrastructure
New Peptide Programs
Quality risk assessment and analytical strategy for novel peptide sequences and modifications.
Early Analytical Development
Identity confirmation, purity assessment and initial impurity profiling for early-stage programs.
Quality Risk Assessment
Systematic identification of potential quality risks before they become development problems.
Impurity Strategy
Impurity identification, classification and reference material planning for new peptide programs.
Reference Materials
Custom synthesis and characterisation of reference materials for novel peptides and impurities.